Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface

Brain, Behavior, and Immunity

Volumn 23, Issue 2, 2009, Pages 149-158

  Miller, Andrew H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anterior cingulate cortex; Basal ganglia; Brain imaging; Cytokine; Depression; Dopamine; Inflammation; Innate immune system; Interferon alpha; Serotonin

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; DOPAMINE; ETANERCEPT; GALANTAMINE; HOMOVANILLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOAMINE; PAROXETINE; PLACEBO; QUINOLINIC ACID; RECOMBINANT ALPHA2B INTERFERON; RESERPINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALERTNESS; ANHEDONIA; ANIMAL BEHAVIOR; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ANXIETY; BASAL GANGLION; BEHAVIOR CHANGE; BIOMECHANICS; BRAIN FUNCTION; CEREBROSPINAL FLUID ANALYSIS; CINGULATE GYRUS; CLINICAL TRIAL; CLONAL ANERGY; CONCENTRATION LOSS; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; ENZYME ACTIVATION; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GLUCOSE METABOLISM; HEALING; HEPATITIS C; HUMAN; HYPERTENSION; HYPOMANIA; INFLAMMATION; INNATE IMMUNITY; IRRITABILITY; LIFE STRESS; MAJOR DEPRESSION; MANIA; MELANOMA; MEMORY DISORDER; MENTAL STRESS; MONOAMINE METABOLISM; MULTIPLE SCLEROSIS; NEOPLASM; NERVE CELL NETWORK; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEPLETION; PSORIASIS; PSYCHOMOTOR DISORDER; PSYCHOPHYSIOLOGY; REVIEW; RHESUS MONKEY; SCIENTIFIC LITERATURE; SEROTONIN METABOLISM; SEROTONIN UPTAKE; SIGNAL TRANSDUCTION; SLEEP DISORDER; STROKE; SURVIVAL; ANIMAL; ARTICLE; BEHAVIOR; CEREBROSPINAL FLUID; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; ANXIETY; BEHAVIOR; CYTOKINES; DEPRESSION; DOPAMINE; HOMOVANILLIC ACID; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-ALPHA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 58549087919     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2008.08.006     Document Type: Review

References (128)

1. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., and Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 72 (2006) 1605-1621
2. Alexander G.E., DeLong M.R., and Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9 (1986) 357-381
3. Aubert A., Goodall G., Dantzer R., and Gheusi G. Differential effects of lipopolysaccharide on pup retrieving and nest building in lactating mice. Brain Behav. Immun. 11 (1997) 107-118
4. Berger J.R., and Arendt G. HIV dementia: the role of the basal ganglia and dopaminergic systems. J. Psychopharmacol. 14 (2000) 214-221
5. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., Ferstl R., von Eynatten M., Wendt T., Rudofsky G., Joswig M., Morcos M., Schwaninger M., McEwen B., Kirschbaum C., and Nawroth P.P. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl. Acad. Sci. USA 100 (2003) 1920-1925
6. Bisoendial R.J., Kastelein J.J., and Stroes E.S. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 195 (2007) e10-e18
7. Borland L.M., and Michael A.C. Voltammetric study of the control of striatal dopamine release by glutamate. J. Neurochem. 91 (2004) 220-229
8. Bouzakri K., and Zierath J.R. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J. Biol. Chem. 282 (2007) 7783-7789
9. Brown A.S., and Gershon S. Dopamine and depression. J. Neural. Transm. Gen. Sect. 91 (1993) 75-109
10. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., and Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry (2008)
11. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., and Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26 (2002) 643-652
12. Capuron L., and Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 56 (2004) 819-824
13. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., and Miller A.H. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol. Psychiatry 54 (2003) 906-914
14. Capuron L., Pagnoni G., Demetrashvili M., Woolwine B.J., Nemeroff C.B., Berns G.S., and Miller A.H. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol. Psychiatry 58 (2005) 190-196
15. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., and Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 32 (2007) 2384-2392
16. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., and Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 160 (2003) 1342-1345
17. Capuron L., and Ravaud A. Prediction of the depressive effects of interferon alpha therapy by the patient's initial affective state. N. Engl. J. Med. 340 (1999) 1370
18. Capuron L., Ravaud A., and Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom. Med. 63 (2001) 376-386
19. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., and Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 7 (2002) 468-473
20. Carter C.S., Braver T.S., Barch D.M., Botvinick M.M., Noll D., and Cohen J.D. Anterior cingulate cortex, error detection, and the online monitoring of performance. Science 280 (1998) 747-749
21. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., and Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
22. Chaudhuri A., and Behan P.O. Fatigue and basal ganglia. J. Neurol. Sci. 179 (2000) 34-42
23. Constant A., Castera L., Dantzer R., Couzigou P., de Ledinghen V., Demotes-Mainard J., and Henry C. Mood alterations during interferon-alpha therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J. Clin. Psychiatry 66 (2005) 1050-1057
24. Cooper J., Bloom F.E., and Roth R.H. The Biochemical Basis of Neuropharmacology. eighth ed. (2003), Oxford University Press, New York
25. Danese A., Moffitt T.E., Pariante C.M., Ambler A., Poulton R., and Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch. Gen. Psychiatry 65 (2008) 409-415
26. Danese A., Pariante C.M., Caspi A., Taylor A., and Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc. Natl. Acad. Sci. USA 104 (2007) 1319-1324
27. Dantzer R., and Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 21 (2007) 153-160
28. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., and Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008) 46-56
29. D'Haenen H., and Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol. Psychiatry 35 (1994) 128-132
30. Di Chiara G., and Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244 (1988) 1067-1080
31. Dunlop B.W., and Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 64 (2007) 327-337
32. Ebert D., Feistel H., Loew T., and Pirner A. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl) 126 (1996) 91-94
33. Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., Chaly T., Robeson W., Margouleff D., Przedborski S., et al. The metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab. 14 (1994) 783-801
34. Eisenberger N.I., and Lieberman M.D. Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cogn. Sci. 8 (2004) 294-300
35. Eisenberger N.I., Lieberman M.D., and Satpute A.B. Personality from a controlled processing perspective: an fMRI study of neuroticism, extraversion, and self-consciousness. Cogn. Affect Behav. Neurosci. 5 (2005) 169-181
36. Feigin A., Fukuda M., Dhawan V., Przedborski S., Jackson-Lewis V., Mentis M.J., Moeller J.R., and Eidelberg D. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 57 (2001) 2083-2088
37. Felger J.C., Alagbe O., Hu F., Mook D., Freeman A.A., Sanchez M.M., Kalin N.H., Ratti E., Nemeroff C.B., and Miller A.H. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol. Psychiatry 62 (2007) 1324-1333
38. Friebe A., Schwarz M.J., Schmid-Wendtner M., Volkenandt M., Schmidt F., Horn M., Janssen G., and Schaefer M. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J. Immunother. (1997) 30 (2007) 333-337
39. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., and Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81 (2002) 1285-1297
40. Goodwill M.H., Lawrence D.A., and Seegal R.F. Polychlorinated biphenyls induce proinflammatory cytokine release and dopaminergic dysfunction: protection in interleukin-6 knockout mice. J. Neuroimmunol. 183 (2007) 125-132
41. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
42. Grace A.A. Dopamine. In: Davis K.L., Charney D.S., Coyle J.T., and Nemeroff C.B. (Eds). Neuropsychopharmacology. The Fifth Generation of Progress (2002), Lippincott Williams and Wilkins, Philadelphia 119-132
43. Gray F., Adle-Biassette H., Chretien F., Lorin de la Grandmaison G., Force G., and Keohane C. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin. Neuropathol. 20 (2001) 146-155
44. Guillemin G.J., Brew B.J., Noonan C.E., Takikawa O., and Cullen K.M. Indoleamine 2, 3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol. 31 (2005) 395-404
45. Guillemin G.J., Wang L., and Brew B.J. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS Dementia Complex. J. Neuroinflamm. 2 (2005) 16
46. Haas H.S., and Schauenstein K. Neuroimmunomodulation via limbic structures-the neuroanatomy of psychoimmunology. Prog. Neurobiol. 51 (1997) 195-222
47. Hart B.L. The behavior of sick animals. Vet. Clin. North Am. Small Anim. Pract. 21 (1991) 225-237
48. Hauser P., Soler R., Reed S., Kane R., Gulati M., Khosla J., Kling M.A., Valentine A.D., and Meyers C.A. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 41 (2000) 439-441
49. Ho B.T., Huo Y.Y., Lu J.G., Tansey L.W., and Levin V.A. Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha. Pharmacol. Biochem. Behav. 42 (1992) 57-60
50. Horikawa N., Yamazaki T., Sagawa M., and Nagata T. A case of akathisia during interferon-alpha therapy for chronic hepatitis type C. Gen. Hosp. Psychiatry 21 (1999) 134-135
51. Irwin M.R., and Miller A.H. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 21 (2007) 374-383
52. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., Bauer J., and Lieb K. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 152 (2000) 383-389
53. Kalin N.H. Behavioral effects of ovine corticotropin-releasing factor administered to rhesus monkeys. Fed. Proc. 44 (1985) 249-253
54. Kamata M., Higuchi H., Yoshimoto M., Yoshida K., and Shimizu T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur. Neuropsychopharmacol. 10 (2000) 129-132
55. Kitagami T., Yamada K., Miura H., Hashimoto R., Nabeshima T., and Ohta T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res. 978 (2003) 104-114
56. Klimek V., Schenck J.E., Han H., Stockmeier C.A., and Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry 52 (2002) 740-748
57. Kluger M.J., Kozak W., Leon L.R., Soszynski D., and Conn C.A. Cytokines and fever. Neuroimmunomodulation 2 (1995) 216-223
58. Krivine A., Force G., Servan J., Cabee A., Rozenberg F., Dighiero L., Marguet F., and Lebon P. Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS dementia complex. J. Neurovirol. 5 (1999) 500-506
59. Kumai T., Tateishi T., Tanaka M., Watanabe M., Shimizu H., and Kobayashi S. Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci. 67 (2000) 663-669
60. Leng A., Mura A., Feldon J., and Ferger B. Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Neurosci. Lett. 375 (2005) 107-111
61. Li W., Knowlton D., Woodward W.R., and Habecker B.A. Regulation of noradrenergic function by inflammatory cytokines and depolarization. J. Neurochem. 86 (2003) 774-783
62. Lou J.S., Kearns G., Benice T., Oken B., Sexton G., and Nutt J. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study. Mov. Disord. 18 (2003) 1108-1114
63. Lou J.S., Kearns G., Oken B., Sexton G., and Nutt J. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov. Disord. 16 (2001) 190-196
64. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995) 11-38
65. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., and Meltzer H. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol. Psychiatry 6 (2001) 475-480
66. Maestripieri D., McCormack K., Lindell S.G., Higley J.D., and Sanchez M.M. Influence of parenting style on the offspring's behaviour and CSF monoamine metabolite levels in crossfostered and noncrossfostered female rhesus macaques. Behav. Brain Res. 175 (2006) 90-95
67. Maier S.F., and Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev. 105 (1998) 83-107
68. Majer M., Welberg L.A., Capuron L., Pagnoni G., Raison C.L., and Miller A.H. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav. Immun. 22 (2008) 870-880
69. Martinot M., Bragulat V., Artiges E., Dolle F., Hinnen F., Jouvent R., and Martinot J. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am. J. Psychiatry 158 (2001) 314-316
70. Mayberg H.S., Starkstein S.E., Sadzot B., Preziosi T., Andrezejewski P.L., Dannals R.F., Wagner Jr. H.N., and Robinson R.G. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann. Neurol. 28 (1990) 57-64
71. McKinney Jr. W.T., Eising R.G., Moran E.C., Suomi S.J., and Harlow H.F. Effects of reserpine on the social behavior of rhesus monkeys. Dis. Nerv. Syst. 32 (1971) 735-741
72. Mendels J., Frazer A., Fitzgerald R.G., Ramsey T.A., and Stokes J.W. Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science 175 (1972) 1380-1382
73. Mentis M.J., McIntosh A.R., Perrine K., Dhawan V., Berlin B., Feigin A., Edwards C., Mattis P., and Eidelberg D. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am. J. Psychiatry 159 (2002) 746-754
74. Meyer J.H., Kruger S., Wilson A.A., Christensen B.K., Goulding V.S., Schaffer A., Minifie C., Houle S., Hussey D., and Kennedy S.H. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12 (2001) 4121-4125
75. Moron J.A., Zakharova I., Ferrer J.V., Merrill G.A., Hope B., Lafer E.M., Lin Z.C., Wang J.B., Javitch J.A., Galli A., and Shippenberg T.S. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 23 (2003) 8480-8488
76. Mossner R., Mikova O., Koutsilieri E., Saoud M., Ehlis A.C., Muller N., Fallgatter A.J., and Riederer P. Consensus paper of the WFSBP task force on biological markers: biological markers in depression. World J. Biol. Psychiatry 8 (2007) 141-174
77. Muller N., and Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 12 (2007) 988-1000
78. Mundt C., Reck C., Backenstrass M., Kronmuller K., and Fiedler P. Reconfirming the role of life events for the timing of depressive episodes. A two-year prospective follow-up study. J. Affect Disord. 59 (2000) 23-30
79. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., and Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N. Engl. J. Med. 344 (2001) 961-966
80. Nagatsu T., and Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 11 (2005) 999-1016
81. Nutt D.J. The role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry 67 Suppl. 6 (2006) 3-8
82. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., and Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry (2008)
83. Pace T.W., Mletzko T.C., Alagbe O., Musselman D.L., Nemeroff C.B., Miller A.H., and Heim C.M. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 163 (2006) 1630-1633
84. Paulus M.P., Feinstein J.S., Simmons A., and Stein M.B. Anterior cingulate activation in high trait anxious subjects is related to altered error processing during decision making. Biol. Psychiatry 55 (2004) 1179-1187
85. Pradhan A.D., and Ridker P.M. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. Eur. Heart J. 23 (2002) 831-834
86. Raison C.L., Borisov A.S., Broadwell S.D., Capuron L., Woolwine B.J., Jacobson I.M., Nemeroff C.B., and Miller A.H. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatry 66 (2005) 41-48
87. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., and Miller A.H. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry (2008)
88. Raison C.L., Capuron L., and Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27 (2006) 24-31
89. Raison C.L., Demetrashvili M., Capuron L., and Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19 (2005) 105-123
90. Raison C.L., Woolwine B.J., Demetrashvili M.F., Borisov A.S., Weinreib R., Staab J.P., Zajecka J.M., Bruno C.J., Henderson M.A., Reinus J.F., Evans D.L., Asnis G.M., and Miller A.H. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment. Pharmacol. Ther. 25 (2007) 1163-1174
91. Reddy P.L., Khanna S., Subhash M.N., Channabasavanna S.M., and Rao B.S. CSF amine metabolites in depression. Biol. Psychiatry 31 (1992) 112-118
92. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., and Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58 (2001) 445-452
93. Rho M.B., Wesselingh S., Glass J.D., McArthur J.C., Choi S., Griffin J., and Tyor W.R. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav. Immun. 9 (1995) 366-377
94. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
95. Roth R.H., and Elsworth J.D. Biochemical pharmacology of midbrain dopamine neurons. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Lippincott Williams and Wilkins, Philadelphia
96. Roy A., Karoum F., and Pollack S. Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch. Gen. Psychiatry 49 (1992) 447-450
97. Rye D.B. The two faces of Eve: dopamine's modulation of wakefulness and sleep. Neurology 63 (2004) S2-S7
98. Salamone J.D., Correa M., Mingote S., and Weber S.M. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J. Pharmacol. Exp. Ther. 305 (2003) 1-8
99. Salamone J.D., Correa M., Mingote S.M., and Weber S.M. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr. Opin. Pharmacol. 5 (2005) 34-41
100. Sanchez M.M., Alagbe O., Felger J.C., Zhang J., Graff A.E., Grand A.P., Maestripieri D., and Miller A.H. Activated p38 MAPK is associated with decreased CSF 5-HIAA and increased maternal rejection during infancy in rhesus monkeys. Mol. Psychiatry 12 (2007) 895-897
101. Schaefer M., Schwaiger M., Pich M., Lieb K., and Heinz A. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 36 Suppl. 3 (2003) S203-S206
102. Schultz W. Multiple dopamine functions at different time courses. Annu. Rev. Neurosci. 30 (2007) 259-288
103. Schwartz A.L., Thompson J.A., and Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol. Nurs. Forum. 29 (2002) E85-90
104. Shah P.J., Ogilvie A.D., Goodwin G.M., and Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol. Med. 27 (1997) 1247-1256
105. Shanks N., Larocque S., and Meaney M.J. Neonatal endotoxin exposure alters the development of the hypothalamic-pituitary-adrenal axis: early illness and later responsivity to stress. J. Neurosci. 15 (1995) 376-384
106. Shuto H., Kataoka Y., Horikawa T., Fujihara N., and Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 747 (1997) 348-351
107. Silverman M.N., Macdougall M.G., Hu F., Pace T.W., Raison C.L., and Miller A.H. Endogenous glucocorticoids protect against TNF-alpha-induced increases in anxiety-like behavior in virally infected mice. Mol. Psychiatry 12 (2007) 408-417
108. Simen B.B., Duman C.H., Simen A.A., and Duman R.S. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol. Psychiatry 59 (2006) 775-785
109. Spetsieris P.G., Moeller J.R., Dhawan V., Ishikawa T., and Eidelberg D. Visualizing the evolution of abnormal metabolic networks in the brain using PET. Comput. Med. Imaging Graph. 19 (1995) 295-306
110. Sunami M., Nishikawa T., Yorogi A., and Shimoda M. Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. Clin. Neuropharmacol. 23 (2000) 59-61
111. Tremblay L.K., Naranjo C.A., Graham S.J., Herrmann N., Mayberg H.S., Hevenor S., and Busto U.E. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch. Gen. Psychiatry 62 (2005) 1228-1236
112. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., and Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35
113. Ursu S., Stenger V.A., Shear M.K., Jones M.R., and Carter C.S. Overactive action monitoring in obsessive-compulsive disorder: evidence from functional magnetic resonance imaging. Psychol. Sci. 14 (2003) 347-353
114. von Giesen H.J., Antke C., Hefter H., Wenserski F., Seitz R.J., and Arendt G. Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings. Arch. Neurol. 57 (2000) 1601-1607
115. von Giesen H.J., Haslinger B.A., Rohe S., Koller H., and Arendt G. HIV Dementia scale and psychomotor slowing-the best methods in screening for neuro-AIDS. J. Neuropsychiatry Clin. Neurosci. 17 (2005) 185-191
116. Wang J.Y., Zeng X.Y., Fan G.X., Yuan Y.K., and Tang J.S. mu- but not delta- and kappa-opioid receptor mediates the nucleus submedius interferon-alpha-evoked antinociception in the rat. Neurosci. Lett. 397 (2006) 254-258
117. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., and Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 10 (2005) 538-544
118. Wichmann T., and DeLong M.R. Oscillations in the basal ganglia. Nature 400 (1999) 621-622
119. Wichmann T., and DeLong M.R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol. 91 (2003) 9-18
120. Wichmann T., and DeLong M.R. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann. N Y Acad. Sci. 991 (2003) 199-213
121. Willeit M., Sitte H.H., Thierry N., Michalek K., Praschak-Rieder N., Zill P., Winkler D., Brannath W., Fischer M.B., Bondy B., Kasper S., and Singer E.A. Enhanced serotonin transporter function during depression in seasonal affective disorder. Neuropsychopharmacology 33 (2007) 1503-1513
122. Willner P., Muscat R., and Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16 (1992) 525-534
123. Wu H.Q., Rassoulpour A., and Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?. J. Neural. Transm. 114 (2007) 33-41
124. Yamada T., and Yamanaka I. Microglial localization of alpha-interferon receptor in human brain tissues. Neurosci. Lett. 189 (1995) 73-76
125. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 711 (1996) 163-174
126. Zhu C.B., Blakely R.D., and Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31 (2006) 2121-2131
127. Zhu C.B., Carneiro A.M., Dostmann W.R., Hewlett W.A., and Blakely R.D. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J. Biol. Chem. 280 (2005) 15649-15658
128. Zorrilla E.P., Luborsky L., McKay J.R., Rosenthal R., Houldin A., Tax A., McCorkle R., Seligman D.A., and Schmidt K. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15 (2001) 199-226